Evidence map›Paper›PMID 38327804›Full record

ArticleMolecular therapy. Methods & clinical development2024

High-titer manufacturing of SARS-CoV-2 Spike-pseudotyped VSV in stirred-tank bioreactors.

Hayley M Todesco, Chris Gafuik, Cini M John, Erin L Roberts, Breanna S Borys, Alexis Pawluk, Michael S Kallos, Kyle G Potts, Douglas J Mahoney

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hayley M TodescoArnie Charbonneau Cancer Institute, Faculty of Medicine, University of Calgary, Calgary, AB, Canada.
Chris GafuikArnie Charbonneau Cancer Institute, Faculty of Medicine, University of Calgary, Calgary, AB, Canada.
Cini M JohnArnie Charbonneau Cancer Institute, Faculty of Medicine, University of Calgary, Calgary, AB, Canada.
Erin L RobertsDepartment of Biomedical Engineering, Schulich School of Engineering, University of Calgary, Calgary, AB, Canada.
Breanna S BorysPharmaceutical Production Research Facility, Schulich School of Engineering, University of Calgary, Calgary, AB, Canada.
Alexis PawlukPharmaceutical Production Research Facility, Schulich School of Engineering, University of Calgary, Calgary, AB, Canada.
Michael S KallosDepartment of Biomedical Engineering, Schulich School of Engineering, University of Calgary, Calgary, AB, Canada.
Kyle G PottsArnie Charbonneau Cancer Institute, Faculty of Medicine, University of Calgary, Calgary, AB, Canada.
Douglas J MahoneyArnie Charbonneau Cancer Institute, Faculty of Medicine, University of Calgary, Calgary, AB, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic highlighted the importance of vaccine innovation in public health. Hundreds of vaccines built on numerous technology platforms have been rapidly developed against SARS-CoV-2 since 2020. Like all vaccine platforms, an important bottleneck to viral-vectored vaccine development is manufacturing. Here, we describe a scalable manufacturing protocol for replication-competent SARS-CoV-2 Spike-pseudotyped vesicular stomatitis virus (S-VSV)-vectored vaccines using Vero cells grown on microcarriers in a stirred-tank bioreactor. Using Cytodex 1 microcarriers over 6 days of fed-batch culture, Vero cells grew to a density of 3.95 ± 0.42 ×10

Indexed as

COVID-19Cytodex 1microcarrieromicronSARS-CoV-2spinner flaskvaccineVeroVSV

Identifiers

PMID38327804
PMCPMC10847022

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.